• Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Auteur:Paridaens, R.; Biganzoli, Laura; Bruning, Peter; Klijn, J G; Gamucci, T; Houston, S; Coleman, R; Schachter, J; Van Vreckem, A; Sylvester, R.; Awada, Ahmad; Wildiers, J; Piccart-Gebhart, Martine
Informations sur la publication:Journal of clinical oncology, 18, 4, page (724-733)
Statut de publication:Publié, 2000-02
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Adenocarcinoma -- drug therapy
Adenocarcinoma -- secondary
Antibiotics, Antineoplastic -- administration & dosage
Antibiotics, Antineoplastic -- adverse effects
Antibiotics, Antineoplastic -- therapeutic use
Antineoplastic Agents, Phytogenic -- administration & dosage
Antineoplastic Agents, Phytogenic -- adverse effects
Antineoplastic Agents, Phytogenic -- therapeutic use
Breast Neoplasms -- drug therapy
Chi-Square Distribution
Cross-Over Studies
Disease Progression
Doxorubicin -- administration & dosage
Doxorubicin -- adverse effects
Doxorubicin -- therapeutic use
Drug Resistance, Neoplasm
Follow-Up Studies
Infusions, Intravenous
Injections, Intravenous
Logistic Models
Middle Aged
Paclitaxel -- administration & dosage
Paclitaxel -- adverse effects
Paclitaxel -- therapeutic use
Proportional Hazards Models
Remission Induction
Survival Rate
Note générale:Clinical Trial
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial